TY - JOUR
T1 - TGF-β-Induced CD4+Foxp3+T cells attenuate acute graft-versus-host disease by suppressing expansion and killing of effector CD8+cells
AU - Gu, Jian
AU - Lu, Ling
AU - Chen, Maogen
AU - Xu, Lili
AU - Lan, Qin
AU - Li, Qiang
AU - Liu, Zhongmin
AU - Chen, Guihua
AU - Wang, Ping
AU - Wang, Xuehao
AU - Brand, David
AU - Olsen, Nancy
AU - Zheng, Song Guo
N1 - Publisher Copyright:
© 2014 by The American Association of Immunologists, Inc.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - The use of TGF-β-induced CD4+Foxp3+T cells (induced regulatory T cells [iTregs]) is an important prevention and treatment strategy in autoimmune diseases and other disorders. However, the potential use of iTregs as a treatment modality for acute graftversus- host disease (aGVHD) has not been realized because they may be unstable and less suppressive in this disease.We restudied the ability of iTregs to prevent and treat aGVHD in two mouse models. Our results showed that, as long as an appropriate iTreggeneration protocol is used, these iTregs consistently displayed a potent ability to control aGVHD development and reduce mortality in the aGVHD animal models. iTreg infusion markedly suppressed the engraftment of donor CD8+cells and CD4+cells, the expression of granzyme A and B, the cytotoxic effect of donor CD8+cells, and the production of T cell cytokines in aGVHD. Therefore, we conclude that as long as the correct methods for generating iTregs are used, they can prevent and even treat aGVHD.
AB - The use of TGF-β-induced CD4+Foxp3+T cells (induced regulatory T cells [iTregs]) is an important prevention and treatment strategy in autoimmune diseases and other disorders. However, the potential use of iTregs as a treatment modality for acute graftversus- host disease (aGVHD) has not been realized because they may be unstable and less suppressive in this disease.We restudied the ability of iTregs to prevent and treat aGVHD in two mouse models. Our results showed that, as long as an appropriate iTreggeneration protocol is used, these iTregs consistently displayed a potent ability to control aGVHD development and reduce mortality in the aGVHD animal models. iTreg infusion markedly suppressed the engraftment of donor CD8+cells and CD4+cells, the expression of granzyme A and B, the cytotoxic effect of donor CD8+cells, and the production of T cell cytokines in aGVHD. Therefore, we conclude that as long as the correct methods for generating iTregs are used, they can prevent and even treat aGVHD.
UR - http://www.scopus.com/inward/record.url?scp=84907192044&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907192044&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1400207
DO - 10.4049/jimmunol.1400207
M3 - Article
C2 - 25156367
AN - SCOPUS:84907192044
SN - 0022-1767
VL - 193
SP - 3388
EP - 3397
JO - Journal of Immunology
JF - Journal of Immunology
IS - 7
ER -